Kiplinger Today


Emerging Markets Hit the Big Time

The contrast between the economic health of the industrialized world and that of many developing countries couldn't be starker. In the U.S., Europe and Japan, unemployment is high, and consumers are curbing spending as they strain to repay loans. From Washington to Tokyo, public finances are a mess. In contrast, emerging markets such as Brazil and India found their feet quickly after the severe global slump. Their banking systems are in ruddy good health, and their economies are expanding nicely. A growing number of middle-class consumers, many seeking to buy their first home and car, are willing and able to take on more debt. And let's not forget growth-demon China, whose government sits atop a pile of $2.4 trillion in foreign-exchange reserves.

The period from 2000 through 2009 was not a lost decade for emerging-markets stocks. They returned 10% annualized, compared with nothing for Standard & Poor's 500-stock index.

We can't say whether the pattern will be the same in the coming decade. But we can say with a high degree of conviction that economic growth will continue to be much more robust in the developing world. David Semple, manager of Van Eck Emerging Markets Fund, predicts that annual growth in emerging nations will be at least four to five percentage points higher than in the developed world over the next three to five years. "The big picture for me boils down to one word: leverage," he says. In short, he means that emerging economies are not weighed down by the ball and chain of excessive debt.

Given the way the world has changed over the past decade, we thought it would be an opportune time to take a look at some high-quality emerging-markets stocks. We started by considering only stocks that trade in the U.S. In choosing our seven favorites, we used many of the same criteria we would employ to pick U.S. companies. We like market leaders with solid balance sheets, high returns on capital and good growth prospects.


With certain exceptions, such as firms that make generic drugs or provide technological services (globally growing industries that help customers reduce costs), we favored companies oriented toward their domestic economies over ones that rely on exports. Why? The old model of an Atlas-like U.S. consumer hoisting the global economy on his shoulders is dead. Many advanced countries will require years to sort out their economic ailments, and that will squeeze imports. Populous giants -- China, India and Brazil in particular -- will be able to tap into their own vast markets.

Emerging markets have a habit of delivering solid returns over the long run, but there are always bumps in the road. So you should buy individual stocks only if you have a high degree of tolerance for risk. (For those who prefer to invest in emerging markets through funds, here are three of our favorites.)

Indian heavyweights

China and India are both humming. But their models for economic development are miles apart. Beijing has made the most out of central control, abundant savings and sound public finances to invest aggressively in a modern infrastructure. That and a bottomless sea of low-cost, productive labor has helped attract vast amounts of foreign capital to manufacturing enterprises. Result: China has surpassed Germany and the U.S. to become the world's leading exporter.

India suffers from budget deficits, pricier capital and an inefficient democratic government, which has erected new infrastructure at a snail's pace. Deficient roads, ports and airports, along with the high cost of money, have hampered manufacturing and export industries.

But India has a longer tradition of private enterprise and an enormous pool of low-cost, high-quality, English-speaking brainpower, particularly in science, math and engineering. The result is world-class, knowledge-based companies, such as Infosys (symbol INFY) and Dr. Reddy's Laboratories (RDY).

Infosys symbolizes the dizzying growth of India's export-oriented information-technology-services industry. In the 1990s, U.S. companies outsourced to India fairly low-value IT services, such as software debugging and "Y2K" testing. But ambitious firms such as Infosys realized that India, with its highly skilled software engineers, could do much more.

Over the past decade, Infosys, which serves more than 500 firms around the world, has moved into increasingly sophisticated services, such as software design and development, systems integration, and consulting. It now competes with the likes of Accenture, IBM and Hewlett-Packard's EDS unit.

From 2000 through 2009, revenues vaulted 23-fold, to $4.6 billion, and profits grew 21-fold, to $1.3 billion. Growth is slowing, but analysts think that this superbly managed company can continue to generate earnings growth of 19% annually over the next three to five years.

The tale of India's pharmaceutical industry -- the country has become pill maker to the world -- is compelling but much less well known than its IT-services story. Founded in 1984 by scientist Anji Reddy, Dr. Reddy's established itself as a producer of bulk ingredients for drugs. But Reddy realized that India, which had an abundance of chemists and chemical engineers, as well as self-sufficiency in the ingredients needed to make drugs, had great potential in the industry. When India's economy opened to the world in the 1990s, Anji Reddy pounced.

First, Dr. Reddy's became a major exporter of raw materials to drug makers. Then it developed a generics business -- making and exporting drugs as they went off-patent in the U.S. and elsewhere. The company invested heavily in research, enabling Dr. Reddy's to be the first to market with many generics and to discover new drug molecules, some of which it has licensed to pharmaceutical heavyweights, such as Novartis and Novo Nordisk. Today, Dr. Reddy's books 84% of its $1.5 billion in annual sales outside of India, with generics representing 72% of the business. S&P thinks Dr. Reddy's can boost earnings 24% a year over the next three years.

Wireless-phone giant

As with many other developing countries, China historically had relatively few land-line phones. Then mobile telephony arrived, and the Chinese seized the technology to leapfrog wired lines. China Mobile (CHL), with strong backing from Beijing (its controlling shareholder) and efficient execution, quickly moved to blanket the country. Today, China Mobile has more than 500 million subscribers, who each pay $11 a month, on average. With a market value of $195 billion, Mobile is the world's largest wireless-phone company.

The investment case for China Mobile has four components: growth, price, yield and currency. Because only 50% of China's adult population has cell-phone service (compared with 90% in the U.S.), the company can continue to add tens of millions of new subscribers each year. The stock sells for only 12 times projected 2010 earnings and yields a respectable 3.7%.

The last piece is currency. China is under enormous international pressure to increase the value of the yuan, which is pegged to the U.S. dollar. Appreciation of the yuan seems probable, a move that would benefit U.S. investors. As a purely domestic company, all of China Mobile's assets and revenues are denominated in yuan.

Editor's Picks From Kiplinger


Permission to post your comment is assumed when you submit it. The name you provide will be used to identify your post, and NOT your e-mail address. We reserve the right to excerpt or edit any posted comments for clarity, appropriateness, civility, and relevance to the topic.
View our full privacy policy


Market Update